Articles tagged with Drug Resistance
Researchers discover how heme bound proteins catalyze hydrogen sulfide signaling in bacteria, leading to stress tolerance and antibiotic resistance. Disrupting this mechanism could inspire new antibiotic strategies against drug-resistant infections.
Ibezapolstat, a new antibiotic, has been shown to be effective in treating Clostridioides difficile (C. diff) infections with high rates of sustained clinical cures. The study found that ibezapolstat killed harmful bacteria without harming the good bacteria in the gut, which helps prevent recurrent C. diff infections.
Researchers at Penn Engineering introduced AMP-Diffusion, a generative AI tool that designed tens of thousands of new antimicrobial peptides with bacteria-killing potential. The most potent AMPs performed as well as FDA-approved drugs without detectable adverse effects.
Researchers are collecting faeces from exotic animals at Dudley Zoo and West Midlands Safari Park to search for phages that can fight bacterial infections. The goal is to create a bio-bank of these phages to develop alternative treatments for life-threatening infections.
Research from the University of South Australia finds that ibuprofen and paracetamol drive antibiotic resistance when used individually, but amplifying it when combined. The study also reveals that common bacteria like E. coli become highly resistant to antibiotics and multiple other medications.
A study at the Garvan Institute of Medical Research found that inactivation of a stress pathway makes ER+ breast cancer cells ignore stress signals, allowing them to evade treatment. The JNK pathway acts as a cellular alarm system, and its disruption leads to treatment resistance.
Researchers from Australia and China have found nine high-priority pathogens in aircraft lavatory wastewater, including some resistant to multiple drugs. The study suggests that monitoring aircraft wastewater could provide an early warning system for the spread of antimicrobial-resistant superbugs.
A new report from the Microbiology Society argues that vaccine deployment can slow AMR emergence. The UK Government is called upon to remove barriers and incentivize public-private collaboration for vaccine development.
Researchers designed over 36 million compounds using generative AI algorithms and computationally screened them for antimicrobial properties. The top candidates show promise against Neisseria gonorrhoeae and Staphylococcus aureus (MRSA) by novel mechanisms that disrupt bacterial cell membranes.
Researchers discovered cancer cells can survive within bone marrow fibroblasts in response to BTK inhibitors, leading to higher survival rates. By blocking CXCR4, treatment may become more effective, potentially increasing complete response rates and moving toward a cure for cancer
Researchers have discovered that combining antimicrobial peptides from bees and frogs can prevent bacteria from mutating quickly, making them a promising alternative to traditional antibiotics. This finding could lead to safer disease control in livestock and agricultural settings.
Researchers have found a way to rearrange atoms in a new generation of malaria drugs to make them more soluble, maintaining their effectiveness against drug-resistant parasites. This breakthrough could lead to an effective successor to artemisinin-based combination therapy.
A new drug pairing of Theobromine and Arainosine has been developed to target the influenza virus's ion channel, effectively blocking its replication and spread. This breakthrough combo outperforms Tamiflu in fighting a range of flu strains, including drug-resistant versions.
A new study found antimicrobial resistant bacteria spreading rapidly among children with severe malnutrition in Niger. The bacteria can cause life-threatening infections like pneumonia and sepsis, which are difficult to treat with antibiotics.
A new clinical trial found that a shorter treatment with fewer drugs may be beneficial for some patients with highly drug-resistant tuberculosis, but not all. The trial showed an 87% effective rate for the shorter regimen compared to 89% for the longer therapy.
Researchers from Korea University have discovered that the protein WEE1 can paradoxically drive immune resistance in cancer cells when located in the cytoplasm. This study suggests that targeting WEE1 with an inhibitor, such as adavosertib, may sensitize tumors to immunotherapy and reinvigorate antitumor immunity.
Researchers have identified a hidden molecular mechanism involving two proteins that allows tumors to resist treatment. A new gelatin-based nanoparticle has been developed to shut down both proteins simultaneously, showing promising results in early studies with mice.
Clinical trials show sutezolid and delpazolid are safer alternatives to linezolid for treating drug-resistant TB, with no cases of nerve damage or blood toxicity reported. The findings suggest these drugs could replace linezolid in treatment regimens.
Researchers identified a point mutation in the normal PML gene that can block the effect of arsenic trioxide, leading to treatment failure and suggesting a new target for genetic screening. This discovery has implications for personalized therapy and may help improve patient outcomes.
Researchers found that immunocompromised animals respond better to phage therapy due to depleted alveolar macrophages, which initially seemed to hinder its efficacy. The study highlights the importance of the immune system in phage therapy and may inform personalized treatment strategies.
The study found that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment outcomes for pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL). Researchers identified a 'multipotency score' to predict clinical outcomes, providing valuable insights into drug resistance and str...
A recent study by National University of Singapore researchers has shown that histone deacetylase inhibitors (HDACi) can protect neurons and limit brain damage following stroke by altering the gene expression of microglia. The treatment was found to reduce brain damage and improve recovery in stroke models, offering new hope for patients.
Researchers from Ben-Gurion University of the Negev have found coral-derived molecules that can disrupt bacterial communication and reduce the virulence of pathogenic bacteria. The combination of these molecules with antibiotics increases effective killing of bacteria, even when they form biofilms.
A protein from insect resilin has been used to create antibacterial coatings that can block bacteria from attaching to surfaces. The coatings were tested on E.coli bacteria and human skin cells, demonstrating 100% effectiveness in repelling bacteria while integrating well with healthy cells.
Researchers have discovered a synthetic compound called infuzide that effectively targets and kills antimicrobial resistant strains of Staphylococcus aureus and Enterococcus in laboratory and mouse tests. The findings suggest that infuzide works differently from other antimicrobials, which may help prevent resistance.
Researchers identified seven bacteria with a potential barrier effect against vancomycin-resistant enterococci. The addition of the bacterial mixture reduced the proliferation of pathogenic bacteria in mice, suggesting a promising therapeutic approach.
Researchers discovered that a specific gene duplication in the fungus Madurella fahalii enables it to neutralize medication, leading to effective treatment challenges. This study highlights the potential of molecular techniques to uncover drug resistance mechanisms and pave the way for targeted therapies.
A potent combination of antimalarial compounds blocks parasite transmission in mosquitoes while circumventing insecticide resistance. The new strategy retains activity even after a year and efficiently kills parasites even when applied to the female mosquito up to four days in advance of infection.
The international conference will focus on translating phage research into clinical reality, exploring key sessions and major speakers. Companies from various sectors are attending the event, highlighting the growing interest in phage therapy.
Researchers have discovered that combining antibiotics with an enzyme called endolysin can protect against infection by resistant bacteria in all bodily organs, including the brain. This breakthrough could lead to a new treatment for meningitis, a life-threatening disease caused by resistant bacteria.
Researchers have developed three-dimensional spheroid cultures that better replicate cell-cell interactions and nutrient gradients, leading to a greater understanding of tumour tissue behaviour and drug responses. The study highlights the importance of mimicking tumour architecture in testing cancer therapies.
Glutathione S-transferases play a critical role in human health, influencing disease development, drug metabolism, and therapeutic interventions. Genetic variations in GSTs can lead to oxidative stress, DNA damage, and resistance to apoptosis, making them key players in disease pathogenesis.
A Phase Ia/Ib trial found that zongertinib demonstrated clinical benefits for patients with advanced HER2-mutant non-small cell lung cancer, particularly those with specific HER2 mutations. The treatment showed a 71% objective response rate and manageable side effects.
A new study at Stellenbosch University found that blocking the enzymes involved in glycolysis could cut off the malaria parasite's primary energy source and kill it. This approach has shown promise for developing new malaria drugs, particularly against resistant parasites.
University of Oklahoma researchers create bioactive sugars to develop novel antibiotics against multi-drug-resistant infections in cancer patients. By using abundant, inexpensive, iron or metal-free, non-toxic blue light, the team can more easily and rapidly synthesize these important carbohydrates.
Researchers at Duke University and colleagues discover a way to improve the uptake of cancer-fighting drugs called PROTACs by leveraging the CD36 protein. This approach delivered up to 23 times more potent treatment without compromising stability or solubility, paving the way for effective medications.
Researchers from the UCLA Health Jonsson Comprehensive Cancer Center are presenting new findings on combination therapies for liver and pancreatic cancers, including a new organoid model for personalized head and neck cancer treatment. Additionally, they are discussing the potential of liquid biopsies for cancer detection and monitoring.
Researchers identified fexofenadine as a potential Met-inhibitor that can overcome osimertinib resistance in NSCLC. The study found that fexofenadine enhances the anticancer effect of osimertinib in both laboratory and mouse models, making it a promising repurposed drug for treating NSCLC.
A new global study found common genetic factors contributing to drug resistance in focal epilepsy, affecting 20 million individuals. Researchers identified specific genetic variants in CNIH3 and WDR26 genes associated with a higher risk of drug-resistant epilepsy.
Researchers found that GSK3β becomes increasingly active in melanoma cells during treatment, helping them survive and adapt despite BRAF inhibitors. Treating resistant cancer cells with a GSK3β inhibitor significantly reduced their growth, suggesting blocking this protein could restore sensitivity to treatment.
A new study has identified ADAR1 as a key factor in suppressing the immune response triggered by lenalidomide, leading to drug resistance in multiple myeloma. The research suggests targeting ADAR1 and the dsRNA pathway could offer promising strategies to overcome resistance.
A University of Ottawa-led team examines the punishing costs of TB care, finding that patients face 'catastrophic' expenses despite free treatment being available in many countries. The review identifies areas for intervention to reduce patient costs and improve sustainable TB mitigation strategies.
Researchers at Mayo Clinic developed a personalized deep brain stimulation platform to treat drug-resistant epilepsy. The study found that this approach reduced seizures while also improving memory and sleep in patients with temporal lobe epilepsy.
A study found that agricultural antifungals, like TBZ, can cause genomic changes in the infectious yeast Candida tropicalis, increasing its resistance. This increase in resistance poses a growing concern for human infections, as many pathogens are becoming resistant to antifungal medicines.
Childhood tuberculosis cases in the EU/EEA have increased by 26% over the past three years, with young children under 15 accounting for 4.3% of all TB cases. The rise in pediatric TB has raised concerns about incomplete treatment, drug-resistant TB, and further transmission.
Researchers discovered that a drug-resistant type of bacteria has adapted to produce antimicrobial genetic tools, eliminating its cousins and replacing them as the dominant strain. The finding validates a system developed at Pitt and UPMC for detecting infectious disease outbreaks.
The European Centre for Disease Prevention and Control (ECDC) reports a rise in tuberculosis cases among children and adolescents in the EU/EEA, with a slight increase in the notification rate from 2.0 to 2.5 per 100,000 population. The highest proportion of paediatric TB was observed in children aged 1 to 4 years old.
Researchers at Institute for Systems Biology (ISB) have discovered a non-genetic adaptation mechanism that allows melanoma cells to evade BRAF inhibitors within hours. By blocking this early response with a combination therapy approach, the study aims to improve treatment outcomes and prolong the effectiveness of existing treatments.
A new study using a microfluidic device found that certain infections may not be as resistant to antibiotics as previously thought. The researchers tested three different antibiotic agents against Pseudomonas aeruginosa and found a gradient of antibiotic activity dependent on the flow rate.
A new study reports that Raman spectroscopy, a noninvasive technique, can distinguish between abnormal FCD type II tissue and healthy brain cells with remarkable accuracy. This method could provide real-time guidance for surgeons to more accurately identify and remove affected tissue during surgery.
Scientists at VCU Massey Comprehensive Cancer Center have discovered a powerful combination therapy that leverages sotorasib and FGTI-2734 to tackle drug resistance in lung cancer. The treatment targets the KRAS G12C mutation, which is responsible for about 14% of non-small cell lung cancers.
Researchers have discovered a new mechanism of how anticancer drugs attack and destroy BRCA mutant cancer cells, including drug-resistant breast cancer cells. The study found that small DNA nicks can expand into large single-stranded DNA gaps, leading to cell death.
Researchers at the Institut Pasteur have gained a better understanding of how mpox variants become resistant to tecovirimat. They found that the drug works by binding two phospholipases together, preventing viral particles from spreading. This knowledge will help develop new antiviral treatments effective across all mpox strains.
Researchers at San Francisco State University have developed a step-by-step machine learning tutorial to detect antibiotic resistance in patients. The team used a publicly available dataset to train four popular machine learning models, which can be easily accessed through Google Colab. The tutorial aims to make machine learning access...
Insilico Medicine has developed a highly selective FGFR2/3 dual inhibitor, which maintains efficacy against resistance mutations and demonstrates a more favorable safety profile compared to existing FGFR inhibitors. The compound showed robust antitumor efficacy in gastric cancer mouse models.
A comprehensive map of Plasmodium knowlesi genes essential for blood infections has been generated, providing insights into drug resistance and informing the development of new therapeutics. The study identified molecular requirements for parasite growth and pinpointed specific genes causing resistance to current antimalarials.
A major clinical trial has identified three new safe and effective regimens for treating drug-resistant tuberculosis, offering faster, safer, and more accessible care. The new treatments show promise in reducing treatment duration and side effects, making them a significant breakthrough in the fight against this infectious disease.
New research reveals that certain antibiotics can suppress the evolution of resistance to phages in E. coli bacteria by targeting a subset of LPS mutants. By modulating these mutants, antibiotics like chloramphenicol and gentamicin reduce phage resistance.
Researchers found significant differences in immune cell populations between healthy individuals and people with schizophrenia, with the CD4/CD8 ratio emerging as a potential biomarker for predicting treatment response. Lower levels of mucosal-associated invariant T cells may signify immune dysregulation in schizophrenia.
Researchers analyzed 7,000 S. aureus samples to identify key genetic changes that enable bacterial survival in humans. The study revealed mutations associated with nitrogen metabolism and immune system evasion strategies.